Predicting Prognosis in Non-Small Cell Lung Cancer Using Number of Nodal Stations
The number of involved nodal stations has the potential to provide a more accurate prognosis in patients with resected non-small cell lung cancer.
The number of involved nodal stations has the potential to provide a more accurate prognosis in patients with resected non-small cell lung cancer.
Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and blocking its interaction with the poliovirus receptor.
The sNDA is supported by data from the phase 3 CROWN study comparing lorlatinib to Xalkori in 296 adults with advanced ALK-positive NSCLC.
The approval was based on data from several clinical trials, including the phase 3 PACIFIC trial and the phase 3 CASPIAN trial.
Topline results from the trial showed that compared with chemotherapy, treatment with cemiplimab-rwlc reduced the risk of death by 32% in the overall trial population.
The MET alteration occurs in 3% to 4% of patients with the condition.
Use of cancer treatment guidelines is not in conflict with shared decision-making; therefore, increasing patients’ access to guidelines may improve the quality of oncologic care.
Overexpression of cannabinoid receptor CB2 may be a prognostic biomarker for NSCLC adenocarcinomas.
The FDA has granted Priority Review to tepotinib for metastatic NSCLC whose tumors have a mutation that leads to METex14 skipping.
Black and Hispanic patients are less likely to receive recommended imaging at time of diagnosis of NSCLC.